Protalix BioTherapeutics (PLX) Net Shares Issued and Repurchased (2017 - 2025)

Protalix BioTherapeutics has reported Net Shares Issued and Repurchased for 9 years, with the latest figure at $1.5 million in Q4 2025.

• On a quarterly basis, Net Shares Issued and Repurchased rose 43.64% year-over-year to $1.5 million in Q4 2025; TTM through Dec 2025 was $1.5 million, a 43.64% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 43.64% from the prior year.
• Net Shares Issued and Repurchased was $1.5 million for Q4 2025 at Protalix BioTherapeutics, up from $1.4 million in the prior quarter.
• The five-year high for Net Shares Issued and Repurchased was $3.5 million in Q4 2022, with the low at $40000.0 in Q2 2022.
• Average Net Shares Issued and Repurchased over 5 years is $1.4 million, with a median of $1.4 million recorded in 2025.
• The sharpest annual moves came in 2021 and 2022: Net Shares Issued and Repurchased sank 58.14% in 2021, then jumped 993.46% in 2022.
• Over 5 years, Net Shares Issued and Repurchased stood at $318255.0 in 2021, then surged by 993.46% to $3.5 million in 2022, then plunged by 51.14% to $1.7 million in 2023, then sank by 40.27% to $1.0 million in 2024, then soared by 43.64% to $1.5 million in 2025.
• The last three Net Shares Issued and Repurchased figures came in at $1.5 million (Q4 2025), $1.4 million (Q3 2025), and $1.0 million (Q4 2024), per Business Quant data.